<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45133">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783626</url>
  </required_header>
  <id_info>
    <org_study_id>1498</org_study_id>
    <nct_id>NCT01783626</nct_id>
  </id_info>
  <brief_title>Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)</brief_title>
  <official_title>Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gambro Lundia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gambro Lundia AB</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evodial +hemodialyzer consists of an evolution of the existing CE marked Evodial device,
      with respect to the hemodialyzer membrane removal characteristics. Different membrane
      prototypes configurations are proposed (3 versions in total), with the objective to modulate
      the hemodialyzer removal capacities (convective and adsorptive capacities).

      Materials(including heparin grafted specifications) as well as the sterilization process are
      identical to the Evodial hemodialyzer. Based on available preclinical data , a clinical
      study is requested to document in vivo the different prototypes removal capacities with
      respect to middle Molecular Weight (MW) reference toxins such as b2 Microglobulin and
      collect data with regards to protein loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy: Beta 2 Microglobulin elimination</measure>
    <time_frame>Change from T0 (dialysis start) at T4 hours (dialysis stop)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: -Elimination of Myoglobin,alpha 1 Microglobulin, alpha amylase and Factor D</measure>
    <time_frame>Change from T0 (dialysis start) at T 4hours (dialysis stop)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy:Profile of ultrafiltrated proteins</measure>
    <time_frame>at T4 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Follow-up of all AEs/SAEs</measure>
    <time_frame>during the study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Measurement of Albumin loss</measure>
    <time_frame>At T4 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative Purified volume (Kt)</measure>
    <time_frame>At T4 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Total protein</measure>
    <time_frame>Change from T0 and T4 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Evodial</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial+ Condition C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial</intervention_name>
    <arm_group_label>Evodial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition B1</intervention_name>
    <arm_group_label>Evodial+ Condition B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition B2</intervention_name>
    <arm_group_label>Evodial+ Condition B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evodial+ Condition C</intervention_name>
    <arm_group_label>Evodial+ Condition C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Anuric patient (diuresis&lt;300ml) ,

          2. ESRD patient treated for at least 3 months,

          3. Patient treated in HDF post-dilution,

          4. Vascular access functioning properly (Qb &gt; 250 ml/min),

          5. Patient aged 18 years or more,

          6. Written consent to participate in the study (informed consent).

        Exclusion Criteria:

          1. Patient with pre-dialytic albuminemia &lt;3.3 g/dl(Nephelometry assay)

          2. Patient with known allergy to heparin or type II heparininduced thrombocytopenia (HIT
             type II);

          3. Patient under guardianship;

          4. Women pregnant or breast feeding;

          5. Patient included in other studies that could interfere with the goals of the current
             study.

          6. Patient that are not affiliated to the health system(beneficiary or dependent).

          7. Patient with positive serology (HIV, Hepatitis).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Loughraieb</last_name>
    <role>Study Director</role>
    <affiliation>Gambro Industries</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Louis-Pasteur (Cherbourg-Octeville)</name>
      <address>
        <city>Cherbourg-Octeville</city>
        <zip>50102</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
